Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYHNV3)

• Drug Name: BLY719 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMYHNV3

Molecule-Related Drug Atlas

Drug(s) Targeting PI3-kinase alpha (PIK3CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[2]
Alpelisib	DMEXMYK	Breast cancer	2C60-2C65	Approved	[3]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[4]
GDC-0032	DMT4QHD	Breast cancer	2C60-2C65	Phase 3	[5]
LY3023414	DMD9KYF	Prostate cancer	2C82.0	Phase 2	[6]
PA-799	DMLSYJQ	Colorectal cancer	2B91.Z	Phase 1/2	[7]
MLN1117	DMCVBQD	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
PWT-33597	DMJY15D	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
HHCYH33	DMRQ4L6	Breast cancer	2C60-2C65	Phase 1	[10]
LY3849524	DM8I68X	Breast cancer	2C60-2C65	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase alpha (PIK3CA)	TTEUNMR	PK3CA_HUMAN	Inhibitor	[1]

References

• [1] In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015 Jan;35(1):175-82.
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [5] Company report (BioOncology)
• [6] Company report (Lilly)
• [7] The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
• [8] National Cancer Institute Drug Dictionary (drug id 714372).
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] Adaptive resistance to PI3Kalpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis. 2021 Jan 14;12(1):85.
• [11] ClinicalTrials.gov (NCT05307705) A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation. U.S.National Institutes of Health.